Novel Therapeutic System for the Treatment of Occult Prostate Cancer

摘要

The goal of this research was to investigate the efficacy and mechanisms of H5BVIFN-beta, a novel immunotherapeutic agent, against prostate cancer in animal models. The purpose of study in the first year was to determine the efficacy of H5BVIFN-beta therapy in suppressing the progression of tumors of TRAMP-L5 murine prostate cancer cells in syngeneic immune competent mice. The authors found that intratumoral delivery of H5BVIFN-beta significantly inhibited the growth of both orthotopic and ecotopic lesions of TRAMP-L5 cells by bout 50 percent. The H5BVIFN-beta therapy moderately but significantly prolonged the survival of tumor-bearing mice, but it could not eradicate TRAMP-L5 tumors in either the orthotopic or ecotopic model.